Status:
RECRUITING
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
Lead Sponsor:
Weizmann Institute of Science
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at...
Eligibility Criteria
Inclusion
- Male and Female
- Age - 18-70
Exclusion
- Consumption of antibiotics 2 months prior to the first day of the experiment.
- Consumption of probiotic supplements 1 month prior to the first day of the experiment.
- Type 1 or type 2 diabetes diagnosis.
- Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.
- Chronic disease - to the discretion of the study doctor.
- Cancer and recent anticancer treatment.
- Psychiatric disorders - to the discretion of the study doctor.
- IBD (inflammatory bowel diseases).
- Alcohol or substance abuse.
- BMI \> 35.
Key Trial Info
Start Date :
April 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05972317
Start Date
April 10 2024
End Date
November 1 2026
Last Update
July 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weizmann institute of science
Rehovot, Israel, Israel